HK2 and colorectal cancer: The negative effect of HK2 overexpression on OS was demonstrated in patients with hepatocellular carcinoma (pooled HR = 2.06, 95% CI = 1.67–2.54, p < 0.001), gastric cancer (pooled HR = 1.72, 95% CI = 1.09–2.71, p = 0.020), colorectal cancer (pooled HR = 2.89, 95% CI = 1.62–5.16, p < 0.001) and others (pooled HR = 2.15, 95% CI = 1.44–3.21, p < 0.001), but not with pancreatic cancer (pooled HR = 1.13, 95% CI = 0.28–4.66, p = 0.864).